TelecomMedia & EntertainmentHealthcareManufacturingClimate & EnergyEducationFintechE-Commerce & MarketplaceConsumer
CDH Investments is a major Chinese alternative asset management firm based in Beijing, founded in 2002 as a spin-off from CICC. The firm invests across private equity, venture capital, private credit, public equities, and real assets, with over $20 billion in assets under management.
Deal activity decreased year-over-year (1 deals in the last 12 months vs 5 prior). Average disclosed round size is $280.2M (across 42 rounds with reported amounts).
Portfolio
34
Fund Size
$1.5B
Top Stage
Series B
Last 12 Mo
3
Team
WM
Wang Mei
Head of RAManaging Partner
WL
Wang Lin
Managing PartnerVenture and Growth Capital
HX
Hu Xiaoling
Managing PartnerPrivate Equity
LG
LI Gang
Executive ChairmanCephei Capital
WS
Wu Shangzhi
Chairman
YW
Ying Wei
Managing PartnerBaifu
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
50 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| II-space | Series E | — | Feb 2026 |
| EEven Realities | Series B | $150M | Jan 2026 |
| AAusperBio | Series B | $63M | Sep 2025 |
| AAusperBio | Series B | $50M | May 2025 |
| AAusperBio | Series B | $73M | Dec 2024 |
| SSpear Bio | Series A | $45M | Jul 2024 |
| RReviR Therapeutics | Series A | $30M | Jul 2024 |
| RRevir | Series A | $30M | Jul 2024 |
| EEven Realities | Series A | — | Jan 2024 |
| RRevir | Seed | $20M | Jan 2022 |
 GemPharmatech | Ipo | $175M | Jan 2022 |
 Iaso Biotherapeutics | Series C | $108M | Sep 2021 |
| IInnovative Cellular Therapeutics | Series C | $40M | Sep 2021 |
 Elpiscience | Series C | $105M | May 2021 |
 SVOLT Energy Technology (蜂巢能源) | Unknown | — | Feb 2021 |
| RRuigu | Series D | $250M | Jan 2021 |
| GGenFleet | Series B | — | Mar 2020 |
| GemPharmatech | Series B | $58.6M | Jan 2020 |
 GlowRoad | Series B | $10M | Apr 2019 |
 Medbanks | Series D | $142M | Jan 2019 |
| RRuigu | Unknown | $42M | Jan 2019 |
| GlowRoad | Series B | $10M | Jan 2019 |
| Elpiscience | Series A | $20M | Dec 2018 |
| II-Mab Biopharma | Series C | $220M | Jun 2018 |
 CASHIFY | Series C | $12M | Jun 2018 |
Page 1 of 2
Top Co-Investors
Source Code Capital5 shared
Lilly Asia Ventures4 shared
Shunwei Capital3 shared
Qiming Venture Partners USA3 shared
5Y Capital3 shared
Hankang Capital3 shared
YuanBio Venture Capital3 shared
IDG Capital3 shared
GLP3 shared
K2VC3 shared
LAV3 shared
ARCH Venture Partners3 shared
Lake Bleu Capital3 shared
Alibaba Group Holding Ltd.3 shared
Yunfeng Capital3 shared
Ally Bridge Group2 shared
Stone Capital2 shared
Flyer One Ventures2 shared
Segra Capital Management2 shared
Sherpa Healthcare Partners2 shared
Last updated: 8 September 2026